Incara Pharmaceuticals has received notice of receiving a European patent for a class of compounds that includes Incara’s lead antioxidant compound for treatment of cancer.

Incara still must file translations of its patent and filed with various individual companies, the company said.

Incara is developing a means of protecting normal cells during radiation treatment and also inhibit the growth of cancer cells.